EU approves expanded indication for Fluarix Tetra for adults and children in influenza.- GlaxoSmithKline.
GSK announced the expanded indication for Fluarix Tetra (Quadrivalent Influenza Vaccine) has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine. Fluarix Tetra has also been approved to be concomitantly administered with pneumococcal polysaccharide vaccines in people aged 50 years and above. Prior to this, the vaccine was approved for active immunisation against influenza A subtype viruses and type B viruses, in people three years of age and older.
Comment: With this approval, healthcare providers would be able to use the same dose of Fluarix Tetra (15 �g of hemagglutinin per virus strain in 0.5 mL) to cover all eligible people from six months of age and older.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins